Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Kyverna Therapeutics, Inc. ( (KYTX) ).
On September 19, 2025, Kyverna Therapeutics, Inc. announced that Dr. Steve Liapis has decided to resign from the board of directors effective September 30, 2025. His resignation is not due to any disagreement with the company. Following his departure, the board will reduce its size from eight to seven members and appoint Christi Shaw to the Audit Committee to fill the vacancy left by Dr. Liapis.
The most recent analyst rating on (KYTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Kyverna Therapeutics, Inc. stock, see the KYTX Stock Forecast page.
Spark’s Take on KYTX Stock
According to Spark, TipRanks’ AI Analyst, KYTX is a Underperform.
Kyverna Therapeutics, Inc. faces significant financial challenges, with consistent losses and zero revenue. The company’s technical indicators and valuation metrics reflect ongoing operational and financial difficulties. Key risks include negative profitability and weak market momentum, which significantly impact the stock’s performance.
To see Spark’s full report on KYTX stock, click here.
More about Kyverna Therapeutics, Inc.
Average Trading Volume: 445,624
Technical Sentiment Signal: Buy
Current Market Cap: $278.5M
For an in-depth examination of KYTX stock, go to TipRanks’ Overview page.